From: A meta-analysis of the efficacy of fibromyalgia treatment according to level of care
All the outcome assessed | Fibromyalgia Impact Questionnaire | Global function | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Std dif in means | Lower | Upper | p-value | Std dif in means | Lower | Upper | p-value | Std dif in means | Lower | Upper | p-value | |
Methodological quality | ||||||||||||
1 to 2 | 1,21 | 0.74 | 1.69 | 0.000 | 1.40 | 0.75 | 2.04 | 0.000 | ||||
3 to 4 | 0.57 | 0.42 | 0.72 | 0.000 | 0.66 | 0.37 | 0.95 | 0.000 | 0.58 | 0.33 | 0.83 | 0.000 |
5 to 6 | 0.23 | 0.14 | 0.31 | 0.000 | 0.36 | 0.18 | 0.55 | 0.000 | 0.37 | 0.22 | 0.51 | 0.000 |
Overall | 0.33 | 0.26 | 0.41 | 0.000 | 0.45 | 0.29 | 0.60 | 0.000 | 0.46 | 0.33 | 0.58 | 0.000 |
Kind of treatment | ||||||||||||
Pharmacological | 0.42 | 0.32 | 0.53 | 0.000 | 0.59 | 0.29 | 0.89 | 0.000 | 0.54 | 0.33 | 0.74 | 0.000 |
Non-pharmacological | 0.63 | 0.43 | 0.83 | 0.000 | 0.52 | 0.26 | 0.79 | 0.000 | 0.52 | 0.26 | 0.79 | 0.000 |
Overall | 0.47 | 0.37 | 0.56 | 0.000 | 0.55 | 0.35 | 0.75 | 0.000 | 0.53 | 0.37 | 0.70 | 0.000 |
Length of treatment (weeks) | ||||||||||||
0 to 8 | 0.73 | 0.57 | 0.89 | 0.000 | 0.83 | 0.35 | 1.30 | 0.001 | 0.82 | 0.50 | 1.14 | 0.000 |
9 to16 | 0.20 | 0.11 | 0.28 | 0.000 | 0.35 | 0.20 | 0.49 | 0.000 | 0.33 | 0.20 | 0.46 | 0.000 |
17 to 24 | 0.36 | 0.14 | 0.58 | 0.001 | 0.73 | 0.29 | 1.16 | 0.001 | 0.35 | -0.01 | 0.71 | 0.055 |
Overall | 0.31 | 0.24 | 0.38 | 0.000 | 0.42 | 0.29 | 0.55 | 0.000 | 0.40 | 0.28 | 0.51 | 0.000 |
Age | ||||||||||||
30 to 39 | 1.41 | 0.95 | 1.88 | 0.000 | 1.41 | 0.97 | 1.85 | 0.000 | 1.41 | 0.97 | 1.85 | 0.000 |
40 to 49 | 0.44 | 0.35 | 0.54 | 0.000 | 0.37 | 0.25 | 0.50 | 0.000 | 0.39 | 0.28 | 0.51 | 0.000 |
50 to 59 | 0.50 | 0.12 | 0.88 | 0.010 | 0.99 | -0.22 | 2.20 | 0.108 | 0.99 | -0.22 | 2.20 | 0.108 |
Overall | 0.48 | 0.39 | 0.58 | 0.000 | 0.46 | 0.34 | 0.58 | 0.000 | 0.47 | 0.35 | 0.58 | 0.000 |
Women (%) | ||||||||||||
< 80 | 3.22 | 0.68 | 5.76 | 0.013 | ||||||||
80 to 89 | 0.70 | 0.49 | 0.91 | 0.000 | 0.96 | 0.30 | 1.62 | 0.004 | 0.85 | 0.46 | 1.24 | 0.000 |
90 to 99 | 0.33 | 0.23 | 0.44 | 0.000 | 0.37 | 0.13 | 0.61 | 0.002 | 0.31 | 0.14 | 0.47 | 0.000 |
100 | 0.40 | 0.25 | 0.55 | 0.000 | 0.50 | 0.23 | 0.78 | 0.000 | 0.50 | 0.23 | 0.78 | 0.000 |
Overall | 0.41 | 0.33 | 0.49 | 0.000 | 0.46 | 0.29 | 0.64 | 0.000 | 0.42 | 0.28 | 0.55 | 0.000 |
Duration of disorder (years) | ||||||||||||
0 to 5 | 0.85 | 0.57 | 1.13 | 0.000 | 0.57 | 0.21 | 0.93 | 0.002 | 0.66 | 0.34 | 0.98 | 0.000 |
6 to10 | 0.36 | 0.27 | 0.45 | 0.000 | 0.45 | 0.26 | 0.64 | 0.000 | 0.38 | 0.22 | 0.54 | 0.000 |
11 to15 | 0.16 | 0.02 | 0.29 | 0.023 | ||||||||
Overall | 0.36 | 0.29 | 0.43 | 0.000 | 0.49 | 0.33 | 0.65 | 0.000 | 0.45 | 0.31 | 0.58 | 0.000 |
Country | ||||||||||||
Germany | 0.36 | 0.17 | 0.56 | 0.000 | ||||||||
Belgium | 0.94 | 0.73 | 1.15 | 0.000 | 1.02 | 0.35 | 1.70 | 0.003 | ||||
Brazil | 1.13 | 0.46 | 1.80 | 0.001 | 0.99 | -0.22 | 2.20 | 0.108 | 0.99 | -0.22 | 2.20 | 0.108 |
Canada | 0.35 | 0.20 | 0.50 | 0.000 | 0.38 | 0.17 | 0.59 | 0.000 | 0.29 | 0.11 | 0.46 | 0.001 |
Finland | 0.10 | -0.08 | 0.28 | 0.283 | ||||||||
Netherlands | 0.09 | -0.21 | 0.39 | 0.567 | ||||||||
Norway | 0.30 | -0.11 | 0.71 | 0.157 | ||||||||
Sweden | 0.35 | 0.05 | 0.64 | 0.022 | 0.45 | 0.03 | 0.88 | 0.038 | 0.45 | 0.03 | 0.88 | 0.038 |
Switzerland | 0.02 | -0.21 | 0.26 | 0.836 | ||||||||
Turkey | 2.19 | 1.31 | 3.08 | 0.000 | 1.41 | 0.97 | 1.85 | 0.000 | 1.41 | 0.97 | 1.85 | 0.000 |
USA | 0.39 | 0.26 | 0.51 | 0.000 | 0.34 | 0.16 | 0.53 | 0.000 | 0.36 | 0.21 | 0.50 | 0.000 |
Overall | 0.36 | 0.30 | 0.43 | 0.000 | 0.46 | 0.33 | 0.58 | 0.000 | 0.42 | 0.31 | 0.52 | 0.000 |